.Nature Medication, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) therapy of people with HER2+ sophisticated bosom cancer cells as well as active or secure brain metastases revealed steady intracranial activity and wide spread effectiveness of T-DXd.